Press Room

2021 CPhI Worldwide

Start
Tuesday, November 09, 2021 - 00:00
End
Thursday, November 11, 2021 - 00:00
Location: Milan, Italy
Booth Number: 2C30
CPhI Worldwide booth 2C30 The Specialist Integrated CDMO | Hovione

Join Hovione at CPhI Worldwide BOOTH # 2C30 and meet the team in whose attentive hands you can place your project.

 

Schedule a meeting at the Hovione's booth (#2C30) or online

 

Schedule a meeting button | Hovione

 

 

 

 

Faster time to market with a Specialized Integrated CDMO 

As a specialized integrated supplier Hovione offers services for drug substance, drug product intermediate and drug product for oral and inhaled solutions. Hovione offers all capabilities at the same site, providing a safer and simpler supply chain route towards commercial manufacturing, helping you bring new medicines to patients at an unprecedented speed.

​​​​​​

We look forward to seeing you at CPhI Worldwide

to present the most reliable and innovative 
end-to-end solutions to help your project succeed

 

 

 

 

 

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025